mitoxantrone has been researched along with Lupus Erythematosus, Systemic in 4 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7." | 1.46 | Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. ( Al-Kali, A; Castro, J; Dueck, A; Ertz-Archambault, N; Finn, L; Foran, J; Gauthier, S; Kelemen, K; Kosiorek, H; Marino, R; Mesa, RA; Palmer, J; Sproat, LZ; Taylor, GE; Tibes, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reder, AT | 1 |
| Centonze, D | 1 |
| Naylor, ML | 1 |
| Nagpal, A | 1 |
| Rajbhandari, R | 1 |
| Altincatal, A | 1 |
| Kim, M | 1 |
| Berdofe, A | 1 |
| Radhakrishnan, M | 1 |
| Jung, E | 1 |
| Sandrock, AW | 1 |
| Smirnakis, K | 1 |
| Popescu, C | 1 |
| de Moor, C | 1 |
| Boddu, PC | 1 |
| Zeidan, AM | 1 |
| Ertz-Archambault, N | 1 |
| Kosiorek, H | 1 |
| Taylor, GE | 1 |
| Kelemen, K | 1 |
| Dueck, A | 1 |
| Castro, J | 1 |
| Marino, R | 1 |
| Gauthier, S | 1 |
| Finn, L | 1 |
| Sproat, LZ | 1 |
| Palmer, J | 1 |
| Mesa, RA | 1 |
| Al-Kali, A | 1 |
| Foran, J | 1 |
| Tibes, R | 1 |
| Sailer, M | 1 |
1 review available for mitoxantrone and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Myeloid disorders after autoimmune disease.
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Genetic Predisposition to Disease; Humans; Immunosuppressiv | 2019 |
3 other studies available for mitoxantrone and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cl | 2021 |
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; Case-Control Stud | 2017 |
[Diagnosis and therapy in multiple sclerosis].
Topics: Adult; Analgesics; Antiviral Agents; Central Nervous System; Diagnosis, Differential; Evoked Potenti | 2010 |